Baird Financial Group
ESPR

Baird Financial Group’s Esperion Therapeutics ESPR Stock Holding History

Baird Financial Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-21,254
Closed -$1.09M – 1513
2020
Q2 		$1.09M Buy
+21,254
New +$889K ﹤0.01% 901
2020
Q1 		– Sell
-18,829
Closed -$1.12M – 1461
2019
Q4 		$1.12M Buy
18,829
+305
+2% +$13.7K ﹤0.01% 933
2019
Q3 		$679K Buy
18,524
+849
+5% +$33.6K ﹤0.01% 1082
2019
Q2 		$823K Buy
+17,675
New +$830K ﹤0.01% 1055
2016
Q2 		– Sell
-10,240
Closed -$173K – 1211
2016
Q1 		$173K Buy
+10,240
New +$165K ﹤0.01% 1167

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Baird Financial Group's ESPR Position: Q3 2020 in Review

Baird Financial Group sold out of Esperion Therapeutics (ESPR) in Q3 2020, closing a stake of 21,254 shares — an estimated $1.09M sold.

Baird Financial Group first reported a position in ESPR in Q1 2016 and held it in 5 quarters. The position peaked at $1.12M in Q4 2019. 166 funds tracked by Wall St. Rank hold ESPR as of Q3 2020.

  • Baird Financial Group reported no remaining Esperion Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Baird Financial Group sold 21,254 Esperion Therapeutics shares in Q3 2020, an estimated $1.09M.
  • Baird Financial Group first reported a position in Esperion Therapeutics in Q1 2016 and held it in 5 quarters.
  • Baird Financial Group's Esperion Therapeutics position peaked at $1.12M in Q4 2019.
  • 166 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2020.

Based on Baird Financial Group's 13F filing for Q3 2020, filed 12 Nov 2020.